Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
8.34M
-
Number of holders
-
7
-
Total 13F shares, excl. options
-
30K
-
Shares change
-
-59
-
Total reported value, excl. options
-
$152K
-
Value change
-
-$300
-
Number of buys
-
3
-
Number of sells
-
-2
-
Price
-
$5.06
Significant Holders of Pasithea Therapeutics Corp. - Common Stock, $0.0001 par value per share (KTTA) as of Q2 2024
8 filings reported holding KTTA - Pasithea Therapeutics Corp. - Common Stock, $0.0001 par value per share as of Q2 2024.
Pasithea Therapeutics Corp. - Common Stock, $0.0001 par value per share (KTTA) has 7 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30K shares
of 8.34M outstanding shares and own 0.36% of the company stock.
Largest 8 shareholders include ADAR1 Capital Management, LLC (27.7K shares), Tower Research Capital LLC (TRC) (1.81K shares), Royal Bank of Canada (250 shares), JPMORGAN CHASE & CO (150 shares), FMR LLC (49 shares), UBS Group AG (38 shares), BANK OF AMERICA CORP /DE/ (6 shares), and WELLS FARGO & COMPANY/MN (0 shares).
This table shows the top 7 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.